ACHFF (Arch Biopartners) Common Stock : $12.54 Mil (As of Dec. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Arch Biopartners Common Stock?

Arch Biopartners's quarterly common stock increased from Mar. 2024 ($11.86 Mil) to Sep. 2024 ($12.86 Mil) but then declined from Sep. 2024 ($12.86 Mil) to Dec. 2024 ($12.54 Mil).

Arch Biopartners's annual common stock increased from Sep. 2022 ($11.66 Mil) to Sep. 2023 ($11.74 Mil) and increased from Sep. 2023 ($11.74 Mil) to Sep. 2024 ($12.86 Mil).

Arch Biopartners Common Stock Historical Data

The historical data trend for Arch Biopartners's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arch Biopartners Common Stock Chart

Arch Biopartners Annual Data

Trend

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

Common Stock

Get a 7-Day Free Trial

10.37

11.65

11.66

11.74

12.86

Arch Biopartners Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Sep24	Dec24
Common Stock	Get a 7-Day Free Trial															11.74	11.84	11.86	12.86	12.54

Arch Biopartners Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Arch Biopartners Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arch Biopartners Inc (OTCPK:ACHFF) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

ARCH:Canada

Address

545 King Street West, Toronto, ON, CAN, M5V 1M1

Website

https://www.archbiopartners.com

Arch Biopartners Inc is a late-stage clinical trial company focused on preventing acute kidney injury and organ damage caused by inflammation. The company is developing a platform of novel drugs that target the dipeptidase-1 (DPEP1) inflammation pathway, which is prevalent in the kidneys, lungs, and liver.